Obesity Drug Wegovy Found to Prevent Heart Attacks, Strokes in Major Trial
The active ingredient in Wegovy is called semaglutide. It’s a synthetic version of our body’s GLP-1 hormone, which plays an important role in regulating our metabolism.Among other things, GLP-1 drugs promote insulin secretion. For over a decade, these drugs have been approved to help manage type 2 diabetes, including Novo Nordisk’s Ozempic, which similarly contains semaglutide.
The SELECT trial enrolled more than 17,000 adults across 41 countries. Volunteers were overweight or obese individuals with no prior history of diabetes but who had pre-existing cardiovascular disease and were over the age of 45. They were randomized to receive the highest dose of Wegovy or a placebo, in conjunction with standard care. For up to five years, the volunteers were monitored for major heart problems, including cardiovascular-related deaths and nonfatal heart attacks and strokes.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Read more »
Wegovy Reduces Risk of Heart Attack and Stroke in Major Cardiovascular TrialA major clinical trial has shown that the weight loss drug Wegovy can reduce the risk of heart attack, stroke, or heart disease-related death by 20% in people with cardiovascular disease, marking the first time a weight loss drug has demonstrated such protective effects.
Read more »
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Read more »
Psychiatrists Prescribe Wegovy for Medication-Induced Weight GainPsychiatrists are increasingly prescribing the popular weight-loss drug Wegovy to patients who gain weight from medicines used to treat mental disorders, such as schizophrenia or bipolar disorder.
Read more »
Morgan Stanley predicts Eli Lilly shares to rally on Novo's obesity drug dataMorgan Stanley believes that the positive data on Novo Nordisk's obesity drug Wegovy will also benefit Eli Lilly, leading to a potential increase in its stock value. Novo Nordisk's shares surged by 15% following the release of late-stage trial data, which demonstrated that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo.
Read more »
GLP Capital Raises $556 Million for Renewable Investment in ChinaGLP Capital Partners, an asset manager, has raised 4 billion yuan ($556.17 million) from China's green development fund and state-owned energy investment firm for renewable energy investments in China. The overall investment of the fund is expected to reach about 20 billion yuan, targeting wind, solar, energy storage infrastructure, and related energy management solutions.
Read more »